Who Paid My Doc
Tammy Russo
Nurse Practitioner, Psychiatric/Mental Health Niskayuna, NY Nurse Practitioner
NPI 1093976003 CMS profile 11189521
2141 Eastern Pkwy, Niskayuna, NY 12309
General payments
$568,227
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Tammy Russo of Niskayuna, NY is reported in the CMS Open Payments database as having received $568,227 across 1,296 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $253,252 | 394 | |
| 2024 | General | $145,855 | 300 | |
| 2023 | General | $96,702 | 306 | |
| 2022 | General | $46,854 | 167 | |
| 2021 | General | $25,564 | 129 |
Beside peers
- Tammy Russo
- Nurse Practitioner, Psychiatric/Mental Health median
- Middle half of Nurse Practitioner, Psychiatric/Mental Health
- National median
In program year 2025, general payments to Tammy Russo were reported at $253,252. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.
Show as a table
| Year | Tammy Russo | Nurse Practitioner, Psychiatric/Mental Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $25,564 | $166 | $54–$482 | $132 |
| 2022 | $46,854 | $195 | $66–$559 | $149 |
| 2023 | $96,702 | $233 | $82–$673 | $160 |
| 2024 | $145,855 | $236 | $84–$688 | $164 |
| 2025 | $253,252 | $258 | $93–$764 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
820
Drug cost
$295,185
Branded share of claims
34.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Austedo Xr Deutetrabenazine | Brand | 14 | $100,855 | |
| Vraylar Cariprazine Hcl | Brand | 66 | $100,410 | |
| Caplyta Lumateperone Tosylate | Brand | 27 | $57,059 | |
| Rexulti Brexpiprazole | Brand | 14 | $20,098 | |
| Adderall Xr Dextroamphetamine/Amphetamine | Brand | 11 | $4,519 | |
| Vascepa Icosapent Ethyl | Brand | 11 | $2,226 | |
| Fluvoxamine Maleate | Generic | 60 | $1,998 | |
| Divalproex Sodium Er Divalproex Sodium | Brand | 14 | $945 | |
| Bupropion Xl Bupropion Hcl | Brand | 30 | $706 | |
| Quetiapine Fumarate | Generic | 29 | $685 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 17 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| CAPLYTA |
|
$89,231 | 27 | — |
| VRAYLAR |
|
$19,255 | 66 | — |
| Qelbree |
|
$15,827 | — | — |
| LYBALVI |
|
$9,286 | — | — |
| Austedo XR |
|
$6,975 | 14 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 17 in the dashboard with a free accountRecords
1,296 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Psychiatric/Mental Health in New York
Carrie Edick
Nurse Practitioner, Psychiatric/Mental Health · Schenectady, NY
Eric Spronz
Nurse Practitioner, Psychiatric/Mental Health · Centereach, NY
Terry Jo Brooks-Devlin
Nurse Practitioner, Psychiatric/Mental Health · Tonawanda, NY
Kevin Siewers
Nurse Practitioner, Psychiatric/Mental Health · Staten Island, NY
Daniel Breeyear
Nurse Practitioner, Psychiatric/Mental Health · Niskayuna, NY
Elijah Stevens
Nurse Practitioner, Psychiatric/Mental Health · Binghamton, NY
Related records
Nurse Practitioner, Psychiatric/Mental Health in New York
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Psychiatric/Mental Health
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.